A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507415-35-00

Acronym

TILD-19-07

Enrollment

204

Registered

2024-05-31

Start date

2021-01-15

Completion date

Unknown

Last updated

2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Brief summary

The proportion of subjects who achieve ACR20 at Week 24

Interventions

DRUGIlumetri 100 mg solution for injection in pre-filled syringe

DRUGtildrakizumab placebo solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The proportion of subjects who achieve ACR20 at Week 24	—

Countries

Czechia, Estonia, Germany, Italy, Poland, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026